Equivalent Benefit of Rapamycin and a Potent mTOR ATP-Competitive Inhibitor, MLN0128 (INK128), in a Mouse Model of Tuberous Sclerosis

Molecular Cancer Research - United States
doi 10.1158/1541-7786.mcr-12-0605
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Equivalent Benefit of mTORC1 Blockade and Combined PI3K-mTOR Blockade in a Mouse Model of Tuberous Sclerosis

Molecular Cancer
Cancer ResearchOncologyMolecular Medicine
2009English

Rapamycin Prevents Epilepsy in a Mouse Model of Tuberous Sclerosis Complex

Annals of Neurology
Neurology
2008English

Survival Benefit and Phenotypic Improvement by Hamartin Gene Therapy in a Tuberous Sclerosis Mouse Brain Model

Neurobiology of Disease
Neurology
2015English

Analysis of a Mouse Skin Model of Tuberous Sclerosis Complex

PLoS ONE
Multidisciplinary
2016English

Correction: An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-Resistant Functions of mTORC1.

Journal of Biological Chemistry
BiochemistryCell BiologyMolecular Biology
2020English

Efficacy of Rapamycin in Tuberous Sclerosis–Associated Hypopigmented Macules

JAMA Dermatology
DermatologyMedicine
2015English

Retraction: Mammalian Target of Rapamycin Inhibitors for Treatment in Tuberous Sclerosis

Korean Journal of Pediatrics
Child HealthPediatricsPerinatology
2013English

Successful Treatment of Subungual Fibromas of Tuberous Sclerosis With Topical Rapamycin

JAMA Dermatology
DermatologyMedicine
2014English

Ku-0063794 Is a Specific Inhibitor of the Mammalian Target of Rapamycin (mTOR)

Biochemical Journal
BiochemistryCell BiologyMolecular Biology
2009English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy